## VRTX: Vertex Pharmaceuticals Incorpor - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($429.50)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Wells Fargo Adjusts PT on Vertex Pharmaceuticals to $515 From $460, Maintains Overweight Rating**
- Source: marketscreener.com | 20251210T121626 | Somewhat-Bullish | Relevance: 100%
- Wells Fargo has updated its price target for Vertex Pharmaceuticals, increasing it to $515 from $460 while maintaining an Overweight rating on the stock. This adjustment reflects the financial institution's continued positive outlook on the pharmaceutical company. The article also touches upon recent news regarding Vertex, including new data presented on CASGEVY and insider share transactions.

**2. Vertex Pharmaceuticals (VRTX): Assessing Valuation After a Strong Multiâ€‘Quarter Run and Recent Pullback**
- Source: Simply Wall Street | 20251210T100849 | Somewhat-Bullish | Relevance: 100%
- Vertex Pharmaceuticals (VRTX) has seen strong performance over the past year despite a recent pullback, drawing investor attention. The company is considered 10% undervalued with a fair value of $485.36, driven by successful new product launches and anticipated margin improvements. However, reliance on cystic fibrosis therapies and potential regulatory setbacks pose risks to this optimistic outlook.

**3. MASTERINVEST Kapitalanlage GmbH Purchases Shares of 5,784 Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251214T180904 | Somewhat-Bullish | Relevance: 100%
- MASTERINVEST Kapitalanlage GmbH initiated a new position in Vertex Pharmaceuticals (NASDAQ:VRTX) during Q2, acquiring 5,784 shares valued at approximately $2.575 million. Other major institutions like Norges Bank, Price T. Rowe Associates, Jennison Associates, Vanguard Group, and Alliancebernstein L.P. also made significant moves in VRTX stock, with many increasing their stakes. Conversely, insiders have been net sellers, offloading over 150,000 shares worth $67.33 million in the last 90 days.

**4. Vertex Pharmaceuticals Incorporated $VRTX Stake Increased by Westwood Holdings Group Inc.**
- Source: MarketBeat | 20251214T140130 | Somewhat-Bullish | Relevance: 100%
- Westwood Holdings Group Inc. significantly increased its stake in Vertex Pharmaceuticals (VRTX) by 108.5% during the second quarter, now holding 154,217 shares worth $68,657,000. Other institutional investors like Vanguard Group Inc. and Jennison Associates LLC also increased their positions. Analyst ratings for VRTX show a "Moderate Buy" consensus with a target price of $498.42, and the company recently surpassed Q2 earnings per share estimates.

**5. Lazard Asset Management LLC Has $213.83 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251214T134930 | Neutral | Relevance: 100%
- Lazard Asset Management LLC has reduced its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 9.8%, now holding 480,310 shares valued at $213.83 million. Insider selling has also occurred, with executives offloading shares worth millions. Despite this, Vertex Pharmaceuticals reported strong Q3 earnings, beating analyst expectations, and carries a "Moderate Buy" consensus rating with a $498.42 price target.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $515 | $460 | +12% |
| 2025-12-05 | Morgan Stanley | $564 | $516 | +9% |
| 2025-12-03 | Morgan Stanley | $516 | $438 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-05 | Morgan Stanley | main | Overweight |
| 2025-12-03 | Morgan Stanley | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($3.52M) |
| Sells | 10 ($11.24M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Capital World Invest: 10.2% (-9.8%)
- Vanguard Group Inc: 9.5% (+1.0%)
- Blackrock Inc.: 8.8% (+1.7%)
- Capital Research Glo: 6.5% (+2.8%)
- JPMORGAN CHASE & CO: 5.1% (+119.3%)

### Key Risks

1. Heavy insider selling: $11M sold (10 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +13%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +3.1% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.58 indicates undervaluation relative to growth. Forward P/E 22.3x stretched relative to 10% growth. Quality metrics strong (ROE 22%, ROA 12%, margin 31%). Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.44), $1.1B free cash flow. Analyst sentiment positive (3 raises, avg +13%). Insider selling cluster ($11.2M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $115.9B |
| Beta | 0.32 |
| 52W Range | $362.50 - $519.68 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.58 |
| Forward P/E | 22.3 |
| Current P/E | 24.5 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.4% to 2.7% (+3.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.3pp (needs >3.0% for momentum thesis). MRS_5 at 3.1% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +MUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.68% (CS: 61) | Neutral |
| RSI_14 | 60.1 | Neutral |
| MACD Histogram | 0.47 | Bullish |
| vs SMA20 | 1.033x | Above |
| vs SMA50 | 1.061x | Above |
| vs SMA200 | 1.023x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $452.04
- **Stop Loss:** $429.50 (5.0% risk)
- **Target:** $474.58 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 44
- **Position Value:** $19,889.76
- **Portfolio %:** 19.89%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-09 (Est: $5.17)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.58 | $4.80 | +4.9% |
| 2025Q2 | $4.25 | $4.52 | +6.3% |
| 2025Q1 | $4.29 | $4.06 | -5.4% |
| 2024Q4 | $4.02 | $3.98 | -1.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*